Register entry
Pfizer Manufacturing Deutschland GmbH
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 30
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
3030 active NDC listings: 30 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 30.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 11 |
| capsule | 9 |
| tablet | 8 |
| tablet, film coated, extended release | 2 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| pfizer manufacturing deutschland gmbh | 30 |
Catalogue
Marketed products
30| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | PREGABALIN | capsule | 53869-1010DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | capsule | 53869-1011DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | capsule | 53869-1012DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | capsule | 53869-1013DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | capsule | 53869-1014DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | capsule | 53869-1016DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | capsule | 53869-1018DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | capsule | 53869-1019DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | tablet, film coated, extended release | 53869-1473DRUG FOR FURTHER PROCESSING |
| - | PREGABALIN | tablet, film coated, extended release | 53869-2347DRUG FOR FURTHER PROCESSING |
| - | abrocitinib | tablet, film coated | 53869-1235DRUG FOR FURTHER PROCESSING |
| - | abrocitinib | tablet, film coated | 53869-1335DRUG FOR FURTHER PROCESSING |
| - | abrocitinib | tablet, film coated | 53869-1435DRUG FOR FURTHER PROCESSING |
| - | apixaban | tablet, film coated | 53869-0893DRUG FOR FURTHER PROCESSING |
| - | apixaban | tablet, film coated | 53869-0894DRUG FOR FURTHER PROCESSING |
| - | doxazosin | tablet | 53869-0076DRUG FOR FURTHER PROCESSING |
| - | doxazosin | tablet | 53869-2076DRUG FOR FURTHER PROCESSING |
| - | doxazosin | tablet | 53869-4501DRUG FOR FURTHER PROCESSING |
| - | doxazosin | tablet | 53869-8077DRUG FOR FURTHER PROCESSING |
| - | doxazosin mesylate | tablet | 53869-2710DRUG FOR FURTHER PROCESSING |
| - | doxazosin mesylate | tablet | 53869-2720DRUG FOR FURTHER PROCESSING |
| - | doxazosin mesylate | tablet | 53869-2740DRUG FOR FURTHER PROCESSING |
| - | doxazosin mesylate | tablet | 53869-2780DRUG FOR FURTHER PROCESSING |
| - | ertugliflozin | tablet, film coated | 53869-4875DRUG FOR FURTHER PROCESSING |
| - | ertugliflozin | tablet, film coated | 53869-4876DRUG FOR FURTHER PROCESSING |
| - | nirmatrelvir | tablet, film coated | 53869-2085DRUG FOR FURTHER PROCESSING |
| - | ritlecitinib | capsule | 53869-0334DRUG FOR FURTHER PROCESSING |
| - | sertraline hydrochloride | tablet, film coated | 53869-4900DRUG FOR FURTHER PROCESSING |
| - | sertraline hydrochloride | tablet, film coated | 53869-4910DRUG FOR FURTHER PROCESSING |
| - | sertraline hydrochloride | tablet, film coated | 53869-4960DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing pregabalin
- Cardinal Health 418, Inc.34 sites · 833 NDC
- Viatris Inc.18 sites · 135 NDC
- CIPLA PHARMACEUTICALS LIMITED7 sites · 368 NDC
- Aurobindo Pharma Limited6 sites · 1,453 NDC
- Matrix Pharmacorp Private Limited5 sites · 122 NDC
- LAURUS LABS LIMITED5 sites · 87 NDC
- International Medication Systems, Ltd.3 sites · 2,801 NDC
- ScieGen Pharmaceuticals India Private Limited3 sites · 200 NDC
- Cadila Pharmaceuticals Limited3 sites · 128 NDC
- Zhejiang Huahai Pharmaceutical Technology Co Ltd3 sites · 76 NDC
Enquiry
Common questions
- Is Pfizer Manufacturing Deutschland GmbH FDA approved?
- Pfizer Manufacturing Deutschland GmbH holds no registered establishment of its own; 30 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Pfizer Manufacturing Deutschland GmbH make?
- 30 products are listed under Pfizer Manufacturing Deutschland GmbH in the openFDA NDC Directory, most often as tablet, film coated; capsule; tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.